Asia Pacific Pharma Congress: Agenda: Preconference and Day One

	Tuesday, September 11, 2012 Preconference Symposia (Optional; Choose one)

	7:30 a.m.			Registration Commences
	PRECONFERENCE I			THE BASICS OF COMPLIANCE CONCERNS IN NEGOTIATING, IMPLEMENTING AND MANAGING, AUDITING AND MONITORING THIRD PARTY RELATIONSHIPS
	9:00 a.m.			Welcome and Introductions Mark Bowra Partner, KPMG Advisory (China) Limited, Shanghai
				Peter Chua Compliance Director, Asia Pacific, Covidien, Singapore
				Ronald Goon Senior Director, Business Practices & Compliance, Johnson & Johnson, Singapore
				Michael Hickman, Esq. Senior Counsel, Simmons & Simmons, Shanghai
				Marc L. Miller Partner, KPMG LLP, New York, NY, USA
				Paul Pu Senior Manager, KPMG Advisory (China) Limited, Shanghai
				John Tan Counsel, Reed Smith, Shanghai, China
				Sam Williamson, Esq. Partner, Kirkland & Ellis International LLP, Shanghai
				Helen HaiXiao Zhang, Esq. Partner, Zhong Lun Law Firm, Shanghai
	9:15 a.m.			Identifying and Conducting Due Diligence on Third Party Intermediaries Defining Third Party Intermediaries Assessing the current state -- Sources of information, filtering, cost-effective solutions Defining risk prioritization of third party relationships and the degree and approach of due diligence Red flags you need to consider for different categories of third party relationships Conducting training and monitoring of your third parties Use of corporate intelligence to confirm self-reported information and evaluate integrity of business partners
	10:00 a.m.			Break
	10:15 a.m.			Negotiating with Third Parties to Include Enforceable Rights to Audit and Ongoing Monitoring Best practices in contracting including the use of arbitration and venue specificity Managing and understanding cultural sensitivities to create collaborative results for success Examples of successful negotiations that have resulted in cost effective auditing and monitoring
	11:00 a.m.			Implementing Third Party Audit Rights and Ongoing Monitoring of Relationships Balancing stake holder and regulatory expectations versus practical implementation challenges Enforcing rights and implementing ongoing monitoring without negatively impacting business relationships Examples of successful audits and monitoring relationships
	11:45 a.m.			Q&A
	12:00 p.m.			Adjournment and Lunch on your Own
	MINI PRECONFERENCE II			SOCIAL MEDIA COMPLIANCE ISSUES
	10:30 a.m.			Welcome and Introductions Sue Egan Director and Principal Consultant, Sue Egan Associates; Editor, Life Science Compliance; Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK
				Erinn Hutchinson Partner, Global Pharmaceuticals and Life Sciences, PwC, Philadelphia, PA, USA
				Mai Tran Executive Vice President of Health and Wellness, Ruder Finn Asia, Singapore Presentation Material (Acrobat)
	12:00 p.m.			Adjournment and Lunch on your Own
	MINI PRECONFERENCE III			RESPONDING TO COMPLIANCE INVESTIGATIONS IN THE ASIA PACIFIC REGION - AN INTERACTIVE WORKSHOP
	10:30 a.m.			Welcome and Introductions Yunxia (Kate) Yin Counsel, Ropes & Gray, Hong Kong (Chair)
	12:00 p.m.			Adjournment and Lunch on your Own


	DAY I: Opening Plenary Session - Perspectives on Compliance in China Tuesday, September 11, 2012

	1:00 p.m.			Welcome and Introductions: Asia Pacific Pharma Congress Vision and Overview Manuel Flores Compliance Director Asia Pacific, Bayer (South East Asia) Pte Ltd, Singapore (Co-chair)
				Gareth Lee, Esq. Associate General Counsel and Head of Compliance, Asia Pacific, Allergan Inc., Singapore (Co-chair)
				Shine Yao, MIM Compliance Director, Merck Sharp & Dohme. Shanghai, China (Co-chair)

	1:30 p.m.			Keynote Address: Ethical Business Practice for Pharmaceutical Companies in China Eric Baclet President and General Manager, Lilly China; EBP (Ethical Business Practice) Executive Sponsor, R&D-based Pharmaceutical Association Committee (RDPAC); Former Vice President of Global Marketing, Lilly Neuroscience, Shanghai, China Presentation Material (Acrobat)

	2:00 p.m.			Chinese Domestic Pharma Company Roundtable Yong Hu, Esq. Head, Legal Affairs Department, Sinopharm Group Co. Ltd., Largest Medical and Healthcare Group in China; Directly Managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), Beijing, China
				Glen Ma, Esq. Partner, Clifford Chance, Shanghai, China (Moderator)

	2:45 p.m.			Break

	3:15 p.m.			Chinese Compliance Best Practices Roundtable: Results of the RDPAC Compliance Survey Jennifer Chen, Esq. Legal Director, R&D-based Pharmaceutical Association Committee (RDPAC), Shanghai, China
				Jane Huang, LLM Associate Compliance Director, Eli Lilly China, Shanghai, China
				Shine Yao, MIM Compliance Director, Merck Sharp & Dohme. Shanghai, China
				Eva Yin, MBA China Compliance Officer, AstraZeneca, Shanghai, China
				John Auerbach, MA Partner, Fraud Investigation and Dispute Services, Ernst & Young, Shanghai, China (Moderator) Presentation Material (Acrobat)

	4:45 p.m.			FCPA and UK Bribery Act Updates UK Bribery Act Update Jane de Lozey, Esq. Joint Head of Fraud, Serious Fraud Office, London, UK Presentation Material (Acrobat)
				Discussion Facilitated by: Vivian Robinson, Esq. Partner, McGuireWoods; Former General Counsel of the UK Serious Fraud Office; Former Head, QEB Hollis Whiteman Chambers; Recorder of the Crown Court and Treasurer of Inner Temple, London, UK
				Joseph B. Tompkins, Jr. Partner, Sidley Austin LLP; Former Deputy Chief of the Fraud Section, Criminal Division, United States Department of Justice, Washington, DC, USA

	5:45 p.m.			Adjournment and Networking Reception